Sean Maduck - Corcept Therapeutics Senior Vice President - Commercial
| CORT Stock | USD 52.42 2.72 4.93% |
President
Mr. Sean Maduck is a Vice President of Sales and Marketing of Corcept Therapeutics Incorporated. He has served as our Senior Vice President, Commercial since April 2016. Prior to that, he served as our Vice President, Sales Marketing. Mr. Maduck joined Corcept in 2012, bringing to the company 12 years of pharmaceutical, biotechnology and management experience. From 2002 to 2012, he held positions in the Finance, Portfolio Planning, and Commercial functions at Genentech. Prior to Genentech, he was an investment banking analyst at W.R Hambrecht Company. He currently serves on the Board of Directors of the Cancer Support Community San Francisco Bay Area since 2016.
| Age | 47 |
| Tenure | 8 years |
| Address | 149 Commonwealth Drive, Menlo Park, CA, United States, 94025 |
| Phone | 650 327 3270 |
| Web | https://www.corcept.com |
Latest Insider Transactions
Maduck earned an A.B. from Dartmouth College, a B.E. in Biomedical Engineering from the Thayer School of Engineering at Dartmouth College, and a Masters in Management from the Stanford Graduate School of Business.Sean Maduck Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sean Maduck against Corcept Therapeutics stock is an integral part of due diligence when investing in Corcept Therapeutics. Sean Maduck insider activity provides valuable insight into whether Corcept Therapeutics is net buyers or sellers over its current business cycle. Note, Corcept Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Corcept Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sean Maduck over six months ago Disposition of 17219 shares by Sean Maduck of Corcept Therapeutics at 25.0 subject to Rule 16b-3 |
Corcept Therapeutics Management Efficiency
The company has return on total asset (ROA) of 0.13 % which means that it generated a profit of $0.13 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2577 %, meaning that it created $0.2577 on every $100 dollars invested by stockholders. Corcept Therapeutics' management efficiency ratios could be used to measure how well Corcept Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.18 in 2024. Return On Capital Employed is likely to gain to 0.22 in 2024. At this time, Corcept Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 652.6 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 349.7 K in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Kathleen Veit | Teva Pharma Industries | N/A | |
| Mark Sabag | Teva Pharma Industries | 53 | |
| Katherine Strei | Emergent Biosolutions | 62 | |
| Sven Dethlefs | Teva Pharma Industries | 55 | |
| Hafrun Fridriksdottir | Teva Pharma Industries | 58 | |
| Gianfranco Nazzi | Teva Pharma Industries | 50 | |
| David Stark | Teva Pharma Industries | 55 | |
| Sean Kirk | Emergent Biosolutions | 45 | |
| Keith Choy | Haleon plc | 55 | |
| Filippo Lanzi | Haleon plc | N/A | |
| Robert Kramer | Emergent Biosolutions | 62 | |
| Brendan OGrady | Teva Pharma Industries | 53 | |
| Adam Havey | Emergent Biosolutions | 53 | |
| Lisa Paley | Haleon plc | 57 | |
| Richard Lindahl | Emergent Biosolutions | 60 | |
| Atul Saran | Emergent Biosolutions | 51 | |
| Eliyahu Kalif | Teva Pharma Industries | 51 | |
| Richard Daniell | Teva Pharma Industries | 57 | |
Management Performance
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 |
Corcept Therapeutics Leadership Team
Elected by the shareholders, the Corcept Therapeutics' board of directors comprises two types of representatives: Corcept Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Corcept. The board's role is to monitor Corcept Therapeutics' management team and ensure that shareholders' interests are well served. Corcept Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Corcept Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Hazel Hunt, Chief Officer | ||
| Amy Flood, Chief Officer | ||
| Joseph MD, President, CoFounder | ||
| William PharmD, Chief Officer | ||
| Roberto Vieira, President Oncology | ||
| Gary JD, Chief Secretary | ||
| Gary Robb, CFO, Chief Accounting Officer and Secretary | ||
| Joseph Lyon, Chief Officer | ||
| Monica Tellado, President Markets | ||
| Atabak Mokari, CFO Treasurer | ||
| Sean Maduck, Senior Vice President - Commercial |
Corcept Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Corcept Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.23 % | ||||
| Operating Margin | 0.26 % | ||||
| Current Valuation | 5.4 B | ||||
| Shares Outstanding | 104.78 M | ||||
| Shares Owned By Insiders | 11.51 % | ||||
| Shares Owned By Institutions | 85.40 % | ||||
| Number Of Shares Shorted | 17.05 M | ||||
| Price To Earning | 30.07 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Corcept Stock Analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.